Celadon Pharmaceuticals founder and chief executive James Short tells Proactive that the group is the first medicinal cannabinoid company to list in the UK since GW Pharma.
The regulatory framework for the UK market is different now from when GW Pharma floated, he explains, which means it can generate revenue as well as go down the road of clinical trials.
People have said to Short that the company has a first-mover advantage, and the potential scale of the market is incredible and I "genuinely want other ‘Celadons’ in the UK as well", he adds.